Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-line sintilimab plus platinum-etoposide for advanced small cell lung cancer
ChiCTR2000038354Phase 4Completed
- Sponsor
- Shanghai Pulmonary Hospital
- Start
- Sep 2020
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of sintilimab, cisplatin, carboplatin and etoposide in small cell lung cancer (SCLC), sponsored by Shanghai Pulmonary Hospital. Primary endpoint: 1-year progression-free survival rate. Started Sep 2020; status: completed.
02
Drugs
sintilimabcisplatincarboplatinetoposide
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ChiCTR2000038354.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000038354.